Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial
Respirology · 2026-07 · 31 (7) · 721-731
DOI: 10.1002/resp.70248 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Respirology, online erschienen am 15.04.2026. Verfasst von Can Xia und 24 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. Hauptthemen laut MEDLINE: Pyrimidines, Lung Diseases, Interstitial, Dermatomyositis, Piperidines. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Shanghai Immune Therapy Institute and the Shanghai Hospital Development Center, National Natural Science Foundation of China, Shanghai Municipal Science and Technology Fund.
Abstract (Originalsprache)
Background and Objective The treatment of anti‐melanoma differentiation‐associated gene 5 antibody‐positive dermatomyositis with interstitial lung disease (MDA5 + DM‐ILD) remains a significant clinical challenge. To compare the effectiveness and safety of upadacitinib (UPA) versus tofacitinib (TOFA) upon 6‐month lung transplantation‐free survival in newly diagnosed MDA5 + DM‐ILD patients.
Methods
This multi‐centre cohort study in China enrolled MDA5 + DM‐ILD patients treated from January 2020 to February 2025. Prevalent/incident new users and non‐inferior design along with inverse probability treatment weighting (IPTW) were implemented to emulate randomized controlled trial.
Results
In the eligible cohort, a total of 106 patients were treated with UPA and 328 with TOFA. The crude 6‐month lung transplantation‐free survival rates were 71.7% (76/106) in the UPA group and 67.4% (221/328) in the TOFA group. In the IPTW‐adjusted cohort, UPA showed a trend toward higher survival than TOFA ( p = 0.067), with a weighted risk difference of 10.3% (95% confidence interval −0.4% to 20.2%) meeting the non‐inferiority margin (non‐inferiority p = 0.003). Sensitivity and subgroup analyses showed consistent results, with potentially greater benefit of UPA in incident JAK inhibitor users (as first‐line treatment), monotherapy recipients (without combination with other immunosuppressants except steroid), and those with rapidly progressive ILD. Safety profiles were comparable between groups.
Conclusion
UPA was found to be non‐inferior to TOFA in improving 6‐month lung transplantation‐free survival among patients with MDA5 + DM‐ILD, with comparable safety. image
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
- Department of Rheumatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
- State Key Laboratory of Respiratory Disease, National Clinical Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
- Department of Rheumatology, Huashan Hospital, Fudan University, Shanghai, China.
- Department of Rheumatology, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China.
- Shanghai Immune Therapy Institute, Shanghai, China.
ORCID-Profile: Can Xia, Bingpeng Guo, Qun Luo, Qian Han
Förderung
- Shanghai Immune Therapy Institute and the Shanghai Hospital Development Center
- National Natural Science Foundation of China
- Shanghai Municipal Science and Technology Fund
Zitieren
APA
Xia, C., Wu, W., Lu, S., Ye, Y., Li, J., Wang, R., Xu, W., Chen, Z., Fu, Y., Lyu, X., Wang, K., Fan, W., Li, J., Guo, B., Luo, Q., Han, Q., Xue, Y., Wan, W., Wu, H., …, & Fu, Q. (2026). Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial. Respirology, 31(7), 721-731. https://doi.org/10.1002/resp.70248
Vancouver
Xia C, Wu W, Lu S, Ye Y, Li J, Wang R, et al. Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial. Respirology. 2026;31(7):721-731. doi:10.1002/resp.70248
BibTeX
@article{Xia2026,
author = {Xia, Can and Wu, Wanlong and Lu, Saisai and Ye, Yan and Li, Jingjing and Wang, Runci and Xu, Wenwen and Chen, Zhiwei and Fu, Yakai and Lyu, Xia and Wang, Kaiwen and Fan, Wei and Li, Jia and Guo, Bingpeng and Luo, Qun and Han, Qian and Xue, Yu and Wan, Weiguo and Wu, Huaxiang and Sun, Wenjia and Sun, Li and Wang, Xiaodong and Ye, Shuang and Chen, Dan and Fu, Qiong},
title = {Upadacitinib Versus Tofacitinib in Anti‐ MDA5 ‐Positive Dermatomyositis With Interstitial Lung Disease: A Multi‐Centre Cohort Study Emulating a Target Trial},
journal = {Respirology},
year = {2026},
volume = {31},
number = {7},
pages = {721--731},
doi = {10.1002/resp.70248}
}
EUVIMED